Company Continues Rebranding and GrowthCLEVELAND

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Company Continues Rebranding and GrowthCLEVELAND [January 7] /PRNewswire/ -- DATATRAK International, Inc. (OTCQX: DATA), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced it will soon be trading as DTRK. The new symbol more closely aligns with the company name and will be active January 9, 2013. “Changing our stock symbol is just one small part of recapturing DATATRAK’s leadership position within the eClinical space,” stated Laurence P. Birch, DATATRAK’s Chairman and CEO. “We begin 2013 strategically positioned to deliver perhaps our most impactful software release – our new DATATRAK ONE™ user interface. The user interface is an extension of our new corporate branding and includes improved workflows, enhanced efficiencies, greater flexibility and more user-friendly features.”Birch continued, “Not only is our ‘out of the box’ technology offered at a lower cost but due to its simplicity in design, DATATRAK ONE™ provides easy to deploy mid-study changes, higher site compliance and increased patient safety, resulting in a truly lower total cost of ownership. DATATRAK ONE™ is safely accelerating clinical trial development activities.” About DATATRAKDATATRAK is the leader of unified eClinical® technologies and related services for the clinical trials industry.  Using the DATATRAK ONE™ multi-product, cloud-based clinical research platform, DATATRAK’s Clinical and Consulting Services™ group assists clients in conducting Phase I-IV drug and device studies in multiple languages throughout the world. DATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit www.datatrak.net.Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management’s expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements.  For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company’s report filed with the OTCQX Market on November 14, 2012 announcing its results for the three-month period ending September 30, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.Contact: Lisa Pahl, Director Marketing, DATATRAK International, Inc., +1-979-393-9025

View More
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 37

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 35

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 40

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing the P/E Ratio of Western Alliance: Insights and Trends

Updated Category News Views 123

Understanding the P/E Ratio of Western Alliance In the current market climate, Western Alliance Inc. (WAL) has seen its share price hit $79.17, reflecting a modest increase of 0.47%. Over the past month, however, the stock has experienced a decrease of 6.61%. Interestingly, despite this recent dip, when we look at the yearly perspective, the stock has climbed by 6.77%...

Continue Reading
Hesai Group Innovates Lidar Technology for Cadillac SUVs

Updated Category News Views 219

Hesai Group Powers Cadillac's VISTIQ with Advanced Lidar Technology Hesai Group, a prominent player in lidar technology, has achieved a significant milestone by partnering with SAIC-GM to integrate its advanced AT series lidar system into Cadillac's new all-electric VISTIQ SUV. This integration represents a breakthrough in automotive design and technology, as it is the...

Continue Reading
Jeffersonville Bancorp Reports Strong Q2 Earnings and Dividend

Updated Category News Views 121

Jeffersonville Bancorp Delivers Impressive Earnings for Q2 Jeffersonville Bancorp, Inc. (OTCQB - JFBC) reported robust second quarter results, showcasing a net income of $3,290,000, equivalent to $0.78 per share. This financial performance indicates a notable increase from the previous year's earnings of $3,031,000, or $0.72 per share, reflecting a significant rise in...

Continue Reading
SAS, NPower Team Up: Disrupting Tech Career Access

Updated Category News Views 12

An Unlikely Alliance Fueling Tech Careers Not every day do you see a big-name data firm strut their stuff in the nonprofit world. SAS has teamed up with NPower to flip the script on tech career access. This isn't just a side project—it's a full-throttle mission to drive hardcore data understanding into communities that have long been left hanging. Right here in Cary,...

Continue Reading
America's Emotional Landscape: Loneliness and Division Exposed

Updated Category News Views 216

Understanding the Impact of Societal Division on Emotional Health Most U.S. adults report feeling isolated, in need of more emotional support Loneliness and a sense of emotional disconnection are increasingly shaping the lifes of individuals in America. Recent findings reveal that a significant majority of U.S. adults feel stressed due to societal division. This insight...

Continue Reading